Syndax readies licensing pact with $40M VC round

With a licensing deal waiting in the wings, Waltham, MA-based Syndax announced a $40 million first round of venture financing. Syndax is developing cancer therapies. Two well known biotech funds, Domain Associates and MPM Capital, led the round.

"The financing allows us to execute plans to initiate several clinical trials this year," Syndax chief executive Joanna Horobin said in a statement. "We expect to announce shortly the in-licensing of a lead product candidate, which should move forward rapidly in development."

- check out the release on the round
- read this report from The Boston Globe

ALSO: Surface Logix raised $20 million in its fourth round. The developer--which has programs in cardiovascular, metabolic, inflammatory and fibrotic diseases--has now raised $52 million. Release